Breaking News Instant updates and real-time market news.

APTX

Aptinyx

$3.25

-0.07 (-2.11%)

08:13
06/26/19
06/26
08:13
06/26/19
08:13

Aptinyx presents preclinical data on NYX-783 in alcohol-seeking behavior

Aptinyx announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-783, demonstrating that the product candidate robustly attenuated alcohol-seeking and relapse-like behavior in multiple models of alcohol use disorder. These studies were conducted in collaboration with the Medical University of South Carolina and data are being exhibited in a poster presentation today at the 42nd Annual Research Society on Alcoholism Scientific Meeting in Minneapolis, Minnesota. In the studies being presented, behavior was assessed in two different models of alcohol use disorder in which animals were trained to self-administer ethanol through lever pressing. In the first model, an alcohol dependence model, alcohol dependence was induced in rats by exposing animals to ethanol vapor, with exposure to air used as a comparative control. After alcohol dependence was established, rats were dosed with either 0.1 mg/kg NYX-783, 6 mg/kg NYX-783, or vehicle one hour prior to the first extinction session. During the extinction sessions, animals were exposed to cues previously associated with alcohol intake, however lever pressing no longer resulted in alcohol delivery. Extinction was measured by the number of days to achieve elimination of alcohol-seeking behavior. Three weeks after extinction, rats were evaluated for relapse-like behavior after re-exposure to alcohol associated cues. In the second model, a stress-induced alcohol-seeking model, rats were exposed to a stressor prior to being trained to self-administer ethanol. Stress exposure increased alcohol-seeking behavior and rendered rats resistant to extinction of alcohol-seeking behavior. This approach models the influence of PTSD on substance abuse. Animals were then evaluated during and after the same extinction paradigm as described in the alcohol dependence model.In both the alcohol dependence model and the stress-induced alcohol seeking model, animals dosed with NYX-783 prior to extinction demonstrated a significantly more rapid elimination of alcohol-seeking behavior as compared to vehicle. Animals dosed with NYX-783 prior to extinction also demonstrated significantly less relapse-like behavior when exposed to alcohol-associated cues in the alcohol dependence model or stress-associated cues in the stress-induced alcohol-seeking model. In the stress-induced alcohol seeking model, animals that were only dosed with NYX-783 prior to re-exposure to the stress-associated cue also demonstrated significantly less relapse-like behavior when compared to vehicle-treated rats. The data being presented support the continued evaluation of NYX-783 in human clinical studies and indicate that treatment with NYX-783 may be an effective approach to addressing alcohol abuse in patients with or without comorbid PTSD.

APTX Aptinyx
$3.25

-0.07 (-2.11%)

06/20/19
LEER
06/20/19
INITIATION
Target $12
LEER
Outperform
Aptinyx assumed with an Outperform at SVB Leerink
SVB Leerink analyst Marc Goodman assumed coverage of Aptinyx with an Outperform rating and $12 price target.
03/22/19
BMOC
03/22/19
NO CHANGE
Target $15
BMOC
Outperform
Aptinyx price target lowered to $15 from $18 at BMO Capital
BMO Capital analyst Gary Nachman lowered his price target on Aptinyx to $15 to reflect his longer-term revenue model adjustments, with "additional conservatism" built in for NYX-2925 after its phase 2 trial data suggested that the program is now geared to more advanced diabetic peripheral neuropathy. The analyst is keeping his Outperform rating on Aptinyx shares however, noting that the company's latest quarter results were better-than-expected on lower spending, while its $151M cash position is expected to last the company into 2021.
03/22/19
CANT
03/22/19
NO CHANGE
Target $12
CANT
Overweight
Aptinyx price target lowered to $12 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan lowered his price target for Aptinyx to $12 from $18 following the company's Q4 results and reiterates an Overweight rating on the shares. The target reduction reduction reflects the "overhang" created by the DPN Phase 2 readout, expectations of modest benefit in the fibromyalgia trial reading out in the first half of 2018, and the recent rapastinel trial outcome in depression that raises concerns with Aptinyx's platform more broadly, Duncan tells investors in a research note.
01/18/19
BMOC
01/18/19
NO CHANGE
Target $18
BMOC
Outperform
Aptinyx price target lowered to $18 from $32 at BMO Capital
BMO Capital analyst Gary Nachman lowered his price target on Aptinyx to $18 after its negative result from the phase II study for NYX-2925 in diabetic peripheral neuropathy that "failed to achieve statistical significance on the primary endpoint." The analyst keeps his Outperform rating however and points to the management's "silver lining" of the drug's 50mg dose trending favorably "in a subset not on concomitant medication." Nachman adds that the program still offers "options to move forward with NYX-2925 in chronic pain" patients.

TODAY'S FREE FLY STORIES

03:25
07/24/19
07/24
03:25
07/24/19
03:25
General news
FX Action: USD-CAD has settled back in the lower 1.3100s »

FX Action: USD-CAD has…

03:00
07/24/19
07/24
03:00
07/24/19
03:00
General news
FX Update: The dollar has consolidated recent gains »

FX Update: The dollar has…

COT

Cott Corp.

$12.34

0.05 (0.41%)

20:29
07/23/19
07/23
20:29
07/23/19
20:29
Upgrade
Cott Corp. rating change at Goldman Sachs »

Cott Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 25

    Sep

20:25
07/23/19
07/23
20:25
07/23/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

T

AT&T

$32.09

-0.05 (-0.16%)

, BA

Boeing

$372.91

-0.48 (-0.13%)

20:25
07/23/19
07/23
20:25
07/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

T

AT&T

$32.09

-0.05 (-0.16%)

BA

Boeing

$372.91

-0.48 (-0.13%)

TMO

Thermo Fisher

$293.82

2.07 (0.71%)

NEE

NextEra Energy

$207.31

-2.05 (-0.98%)

UPS

UPS

$105.24

1.25 (1.20%)

ANTM

Anthem

$302.82

1.04 (0.34%)

CAT

Caterpillar

$138.07

2.87 (2.12%)

BSX

Boston Scientific

$42.80

0.3 (0.71%)

NOC

Northrop Grumman

$324.01

0.93 (0.29%)

GD

General Dynamics

$185.92

1.295 (0.70%)

VFC

VF Corp.

$88.25

1.41 (1.62%)

APH

Amphenol

$98.36

1.185 (1.22%)

HLT

Hilton

$95.18

1.95 (2.09%)

FCX

Freeport McMoRan

$11.65

0.16 (1.39%)

SC

Santander Consumer

$25.74

0.49 (1.94%)

KNX

Knight-Swift

$37.87

0.9 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 30

    Oct

  • 13

    Nov

  • 02

    Dec

COT

Cott Corp.

$12.34

0.05 (0.41%)

20:15
07/23/19
07/23
20:15
07/23/19
20:15
Upgrade
Cott Corp. rating change at Goldman Sachs »

Cott Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 25

    Sep

RARX

RA Pharmaceuticals

$33.58

-2.43 (-6.75%)

20:11
07/23/19
07/23
20:11
07/23/19
20:11
Syndicate
RA Pharmaceuticals 4M share Secondary priced at $32.50 »

Jefferies, BMO Capital,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CUTR

Cutera

$24.40

0.19 (0.78%)

20:04
07/23/19
07/23
20:04
07/23/19
20:04
Hot Stocks
Cutera gets approval of Brazil's ANVISA for truSculpt »

Cutera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 13

    Nov

ITCI

Intra-Cellular

$8.18

-3.81 (-31.78%)

19:44
07/23/19
07/23
19:44
07/23/19
19:44
Hot Stocks
Intra-Cellular updates on lumateperone info provided to FDA »

Intra-Cellular Therapies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Sep

SCHW

Charles Schwab

$43.54

0.38 (0.88%)

19:28
07/23/19
07/23
19:28
07/23/19
19:28
Periodicals
Charles Schwab CMO, EVP of investor services to leave, BI says »

Charles Schwab is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

FB

Facebook

$202.38

0.06 (0.03%)

19:26
07/23/19
07/23
19:26
07/23/19
19:26
Periodicals
Facebook CEO must certify compliance under FTC privacy agreement, WSJ says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

AXP

American Express

$128.20

2.19 (1.74%)

19:24
07/23/19
07/23
19:24
07/23/19
19:24
Periodicals
AmEx to refund $1.6M after finding salespeople misrepresented pricing, WSJ says »

American Express is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

OBE

Obsidian Energy

$1.00

0.0087 (0.88%)

19:22
07/23/19
07/23
19:22
07/23/19
19:22
Hot Stocks
Obsidian Energy regains compliance with NYSE listing standards »

Obsidian Energy received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEFT

Euronet

$165.34

1.22 (0.74%)

19:16
07/23/19
07/23
19:16
07/23/19
19:16
Earnings
Breaking Earnings news story on Euronet »

Euronet Worldwide sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Aug

  • 25

    Sep

  • 14

    Nov

EEFT

Euronet

$165.34

1.22 (0.74%)

19:16
07/23/19
07/23
19:16
07/23/19
19:16
Earnings
Euronet Worldwide reports Q2 adjusted EPS $1.69, consensus $1.69 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Aug

  • 25

    Sep

  • 14

    Nov

CALX

Calix

$7.30

0.155 (2.17%)

19:13
07/23/19
07/23
19:13
07/23/19
19:13
Earnings
Calix sees Q3 adjusted EPS 2c-6c, consensus 10c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CALX

Calix

$7.30

0.155 (2.17%)

19:12
07/23/19
07/23
19:12
07/23/19
19:12
Earnings
Calix reports Q2 adjusted EPS (1c), consensus (3c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

WE

We Company

$0.00

(0.00%)

19:06
07/23/19
07/23
19:06
07/23/19
19:06
Periodicals
WeWork eyes September IPO, WSJ reports »

WeWork Companies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIC

Eagle Point Income Company

$0.00

(0.00%)

19:03
07/23/19
07/23
19:03
07/23/19
19:03
Syndicate
Eagle Point Income Company 1.2M share IPO priced at $19.89 »

National Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTS

Tile Shop

$3.08

-0.88 (-22.22%)

18:57
07/23/19
07/23
18:57
07/23/19
18:57
Downgrade
Tile Shop rating change at Telsey Advisory »

Tile Shop downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

AAPL

Apple

$208.85

1.64 (0.79%)

, GOOG

Alphabet

$1,146.62

8.53 (0.75%)

18:57
07/23/19
07/23
18:57
07/23/19
18:57
Periodicals
Apple, Google, Facebook, others petition FCC over VLP Wi-Fi category, Verge says »

Apple (AAPL), Google…

AAPL

Apple

$208.85

1.64 (0.79%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

GOOGL

Alphabet Class A

$1,148.77

9.25 (0.81%)

MSFT

Microsoft

$139.29

0.88 (0.64%)

FB

Facebook

$202.38

0.06 (0.03%)

HPQ

HP Inc.

$21.64

0.2 (0.93%)

QCOM

Qualcomm

$74.10

-1.83 (-2.41%)

INTC

Intel

$51.76

0.4 (0.78%)

AVGO

Broadcom

$300.79

4.68 (1.58%)

MRVL

Marvell

$26.50

0.64 (2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 27

    Oct

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

, TER

Teradyne

$48.09

1.26 (2.69%)

18:56
07/23/19
07/23
18:56
07/23/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Jounce…

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

TER

Teradyne

$48.09

1.26 (2.69%)

EW

Edwards Lifesciences

$195.47

1.55 (0.80%)

MANH

Manhattan Associates

$72.91

1.16 (1.62%)

SNAP

Snap

$14.85

0.71 (5.02%)

TXN

Texas Instruments

$120.05

1.89 (1.60%)

OLBK

Old Line Bancshares

$26.14

(0.00%)

CSL

Carlisle

$132.30

2.445 (1.88%)

CMG

Chipotle

$740.42

-1.88 (-0.25%)

CNI

Canadian National

$91.05

-0.07 (-0.08%)

DFS

Discover

$84.54

2.205 (2.68%)

NAVI

Navient

$13.71

0.27 (2.01%)

WFC

Wells Fargo

$47.20

0.7 (1.51%)

IRBT

iRobot

$89.64

-2.7 (-2.92%)

RHI

Robert Half

$58.81

1.45 (2.53%)

V

Visa

$180.89

0.34 (0.19%)

SGEN

Seattle Genetics

$75.88

-0.22 (-0.29%)

FB

Facebook

$202.38

0.06 (0.03%)

TWTR

Twitter

$37.90

0.32 (0.85%)

AMZN

Amazon.com

$1,994.44

8.51 (0.43%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 03

    Aug

  • 08

    Aug

  • 21

    Aug

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 11

    Sep

  • 23

    Sep

  • 25

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

  • 13

    Nov

  • 24

    Jul

DB

Deutsche Bank

$7.95

0.16 (2.05%)

18:45
07/23/19
07/23
18:45
07/23/19
18:45
Periodicals
Deutsche Bank's credit derivatives seen as hard to offload, Reuters says »

Three bank insiders have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

NHI

National Health Investors

$79.63

0.91 (1.16%)

18:35
07/23/19
07/23
18:35
07/23/19
18:35
Hot Stocks
National Health Investors to invest $7.6M in Colorado community »

National Health Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

RGLS

Regulus

$1.13

-0.07 (-5.83%)

18:32
07/23/19
07/23
18:32
07/23/19
18:32
Hot Stocks
Regulus announces a program update for RGLS4326 »

Regulus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.